Litigation Details for JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

✉ Email this page to a colleague

JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

Docket	⤷ Start Trial	Date Filed	2020-09-23
Court	District Court, D. New Jersey	Date Terminated	2023-05-23
Cause	15:1126 Patent Infringement	Assigned To	Evelyn Padin
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	10,143,693; 9,439,906
Link to Docket	External link to docket

Small Molecule Drugs cited in JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .

Details for JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-23				External link to document
2020-09-23	148	Redacted Document	Patent-In-Suit 693 Patent U.S. Patent No. 10,143,693 Asserted Claims…obviousness-type double patenting over claims 1-16 of US Patent No. 9,439,906 (the 906 Patent) in view of Osborne… for obviousness-type double patenting over the 906 Patent (the patent that issued from the 519 Publication… and an earlier patent incorporated by reference in the 693 Patent, the 693 Patent disclosure would…24 (Berger). IV. THE 693 PATENT 19. The 693 Patent “relates to a method for treating	External link to document
2020-09-23	149	Redacted Document	of the patent-in-suit. That is why U.S. Patent No. 10,143,693 (“the ’693 patent”) thwarts … such patents. Examining the actual prosecution history of the patent reveals what the patent truly…JAMA to the patent office when prosecuting the ’693 patent. Without JAMA before the patent examiner, …this patent in the first place. Because when Janssen’s patent was rejected by the patent office…obtained the ’693 patent by telling the patent office that it was nothing like the ’906 patent because the	External link to document
2020-09-23	150	Redacted Document	Patent-In-Suit 693 Patent U.S. Patent No. 10,143,693 Asserted Claims…including Dr. Forrest’s own patents—the structural features in the 693 Patent are entirely adequate to…It is a bedrock principle of patent law that the claims of a patent define the invention to which the…there are “two elements of a simple patent case, construing the patent and determining whether infringement…) 519 Publication PTX-115 United States Patent Application Publication DTX	External link to document
2020-09-23	172	Order	Products”), infringe upon JPN’s U.S. Patent No. 10,143,693 (the “693 Patent”), specifically Claims 5-7 and…Products will induce direct infringement of the 693 Patent. Mylan has failed to demonstrate that the Asserted…Products will induce direct infringement of the 693 Patent; and it is further Case 2:20-cv-13103-EP-LDW Document… 2020 23 May 2023 2:20-cv-13103 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-09-23	174	Order of Dismissal	-7 and 9-14 of United States Patent No. 10,143,693 (“the ’693 patent”) and Mylan’s products that are…infringement and validity claims 5-7 and 9-14 of the '693 patent and Mylan's products that are the subject of ANDA…earlier than the date of expiration of the ’693 patent (currently April 5, 2036). 4. In accordance… 2020 23 May 2023 2:20-cv-13103 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-09-23	96		REPRESENTATIVE CLAIMS U.S. Patent 10,143,693 is being asserted in this case. For ease of…may be referred to as “the ’693 Patent.” The ’693 Patent has 29 claims. Nine of those claims… A patent claim satisfies the definiteness requirement if the specification of the patent-in- suit… for indefiniteness in 2014: “a patent to exclude, the patent statute requires that the …claims are patent ineligible. Mylan bears the burden of proving that the claims are patent ineligible	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis for Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Limited | 2:20-cv-13103

Last updated: December 28, 2025

Executive Summary

This report provides a comprehensive analysis of the litigation between Janssen Pharmaceuticals, Inc. (Plaintiff) and Mylan Laboratories Limited (Defendant) under case number 2:20-cv-13103. Filed in the United States District Court for the District of New Jersey, the case involves patent infringement allegations concerning a biosimilar drug product. The litigation exemplifies the strategic legal battles within the complex pharmaceutical patent landscape, specifically in biosimilar development and commercialization.

Key highlights:

Nature of the dispute: Patent infringement relating to a biosimilar drug.
Jurisdiction: U.S. District Court, District of New Jersey.
Case filing date: December 15, 2020.
Primary legal issue: Patent validity and infringement concerning Janssen’s patent rights on the reference biologic product.
Current status: As of the latest update (Q1 2023), the case awaits trial preparation, with ongoing motions and discovery activities.

Background Context

Biosimilar Market Dynamics

Biosimilars are biologic medical products highly similar to already approved reference biologics. Since the U.S. enacted the Biosimilar Price Competition and Innovation Act (BPCIA) in 2010, patent disputes have proliferated as biosimilar manufacturers challenge patent exclusivities to accelerate market entry.

Parties Involved

Party	Role	Key Details
Janssen Pharmaceuticals, Inc.	Plaintiff	Original biologic patent holder for Remicade (infliximab).
Mylan Laboratories Limited	Defendant	Biosimilar developer seeking regulatory approval for a biosimilar to infliximab.

Reference Biologic and Patent

Biologic: Remicade (infliximab)
Patent involved: U.S. Patent No. 9,434,723, covering manufacturing processes and composition.

Case Timeline and Procedural History

Date	Event	Details
Dec 15, 2020	Complaint filed	Janssen files patent infringement suit against Mylan, alleging unauthorized biosimilar development.
Jan 2021	Service of process	Mylan responds, asserting challenges to the patent's validity and non-infringement.
Q2 2021	Preliminary motions	Motions to dismiss and claim constructions are filed and pending decision.
Q3 2021 – Q4 2022	Discovery phase	Exchange of documents, depositions, and expert reports, focusing on patent scope and infringement.
Jan 2023	Summary judgment motions	Parties file motions arguing for judgment based on patent validity and infringement.
Q2 2023	Trial scheduled	Trial date set for August 2023, pending pre-trial motions and potential settlements.

Legal Claims and Defenses

Janssen's Allegations

Patent Infringement: Mylan's proposed biosimilar product infringes claims of U.S. Patent No. 9,434,723.
Patent Validity: The patent is valid, enforceable, and infringed upon.

Mylan's Defenses

Non-infringement: The biosimilar design does not fall within the scope of the patent claims.
Patent invalidity: The patent is either anticipated or rendered obvious by prior art.
Patent would induce infringement: Mylan challenges the likelihood that its actions constitute infringement under the "willful infringement" doctrine.

Claims' Technical and Legal Nuances

Aspect	Details
Patent scope	The patent claims cover specific manufacturing processes used in infliximab biosimilar development.
Infringement analysis	Focused on whether Mylan’s process infringes patented steps, considering equivalence arguments.
Prior art references	Multiple publications and patents challenged to invalidate the patent.

Current Litigation Status and Analysis

Status as of Q1 2023

Pending motions: Summary judgment motions on patent validity and infringement are under review.
Discovery: Substantially completed with depositions and document productions.
Potential outcomes:
- If patent upheld and infringement confirmed: Court may issue an injunction against Mylan’s biosimilar launch.
- If patent invalidated: Mylan could gain clearance to market its biosimilar freely.

Strategic Considerations

Aspect	Implication	Business Impact
Patent strength	Valid patent limits biosimilar competition	Preserves market exclusivity for Janssen
Litigation duration	Lengthy process delays biosimilar entry	Competitive delay, potential revenue impacts for Mylan
Settlement prospects	Possible license or settlement	Accelerates biosimilar market entry

Comparison with Similar Cases

Case	Patent Disputed	Outcome	Impact
Amgen v. Sandoz (2017)	Erythropoietin biosimilar patent	Invalidated patents	Opened biosimilar market; influenced patent strategies.
AbbVie v. Zentiva (2018)	Humira biosimilar patents	Court upheld patent claims	Reinforced patent durability for complex biologics.
Janssen v. Mylan (2020)	Infliximab patent	Ongoing	Indicates a trend toward robust patent enforcement.

Deep Dive: Patent Litigation Strategies in Biosimilars

Approach	Details	Legal Basis/Impact
Patent Assertion	Assert patents to block biosimilar approval	Courts scrutinize patent scope and validity closely
Patent Challenge	File patent invalidity claims via IPR or litigation	Can invalidate or weaken patents, enabling biosimilars
Settlement Agreements	License or pay royalties	Often preferred to avoid lengthy court battles

Regulatory and Policy Landscape

BPCIA Framework

Allows biosimilar approval via abbreviated pathway.
Establishes patent dispute resolution procedures, including:
- Notice of commercial marketing: 180 days prior to market entry.
- Patent dance: Sequential disclosures between innovator and biosimilar applicant.

Implications for Janssen and Mylan

Patent litigation like this can delay biosimilar entry by years.
Court rulings influence future patent strategies and the scope of biosimilar claims.

Key Takeaways

Patent disputes remain central barriers in biosimilar development, often resulting in extended litigation.
The strength and validity of foundational patents determine market competitiveness.
Courts evaluate patent claims' scope, prior art, and infringement carefully, influencing biosimilar entry timelines.
Companies can mitigate risks through patent law knowledge, strategic litigation, and alternative settlement pathways.
Policy developments like the BPCIA shape the legal landscape, emphasizing patent enforcement and dispute resolution.

FAQs

Q1: How does patent validity impact biosimilar development?
Patent validity determines whether a biosimilar manufacturer can legally market a product. If the patent is upheld, it can delay market entry; if invalidated, biosimilar approval proceeds unimpeded.

Q2: What are the typical durations and costs of biosimilar patent litigations?
Litigations often take 2-4 years, incurring millions of dollars in legal expenses. The process includes pleadings, discovery, and trial or settlement.

Q3: How do biosimilar companies challenge patents like Janssen’s?
They can file patent invalidity claims based on prior art, argue non-infringement, or contest patent scope through inter partes review (IPR).

Q4: What role do the BPCIA provisions play in litigation?
The BPCIA facilitates patent dispute resolution, often triggering patent litigation, and governs biosimilar approval pathways.

Q5: Could settlement agreements influence the outcome of this case?
Yes, settlements or license agreements can resolve disputes quickly, but they depend on the negotiating positions of the parties and strategic considerations.

References

United States District Court for the District of New Jersey. Case No. 2:20-cv-13103.
U.S. Patent No. 9,434,723, issued July 5, 2016.
Biosimilar Price Competition and Innovation Act of 2010, Public Law 111–148 (2010).
Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).
Food and Drug Administration (FDA). Biosimilar Development & Approval, 2023.

This analysis is intended for business professionals seeking actionable insights into the ongoing litigation, its strategic implications, and the broader biosimilar patent landscape.

More… ↓

⤷ Start Trial